Milton Park Cell Engineering Lunchtime Seminar: Cell and Gene Therapy, BioProcessing

Join us ​​Thursday, December 1st for an in-person seminar on MaxCyte Electroporation Technology hosted in the Thames Meeting Room, Milton Park Innovation Centre.

In this seminar you will find out how to rapidly drive your developmental efforts forward from research to commercialisation, safely, and cost-effectively by leveraging MaxCyte’s flow electroporation technology, whether you are working on cell and gene therapies or in bioprocessing.

Please register to attend the time slot most relevant to your field of work. Lunch will be provided for all attendees.

Agenda:
11:00 am-12:00 pm: Research and clinical scale gene editing for cell and gene therapy applications
12:00 pm-1:00 pm: Lunch
1:00 pm-2:00 pm: A universal GMP-compliant cell engineering platform for large-scale transient protein expression and rapid cell line generation

Register to learn how you can leverage this scalable platform to more efficiently engineer primary cells, stem cells, and cell lines for applications such as cell therapy, biotherapeutics, protein production, vaccines and more.

We will also be offering a clinic throughout the day to book appointments to speak with our scientist, Marianna, to discuss your specific challenges. Please register your interest and we will connect with you to schedule a convenient time. You can also reach me directly - Debra Barberini.

Speakers/Panel

Marianna Romito, PhD

Field Applications Scientist

Maxcyte, Inc.

Read Speaker Bio

Marianna is Field Application Scientist and Cell Therapy Specialist for Europe at MaxCyte, where she supports the scientific activity of customers, collaborators, and prospects. She joined the company in December 2019, after finishing her post-doc on CRISPR-Cas9 and AAV6 HDR-mediated gene correction of IL7RA-deficient hematopoietic stem cells at the UCL Great Ormond Street Institute of Child Health. Her Ph.D. work was focused on the pre-clinical development of HIV-resistant genome-edited T cells using TALEN nucleases at the Albert Ludwig University of Freiburg. Marianna holds two patents on genome and epigenome editing of clinically relevant cells and several publications in high-impact factor journals such as Nature Biotechnology, Nucleic Acids Research, and Nature Communication.

Debra Barberini, PhD

Sales Manager, UK and Ireland

MaxCyte, Inc.

Read Speaker Bio

Debra is the UK and Ireland Sales Manager for MaxCyte supporting customers and partners across both cell and gene therapy and bioprocessing fields. Debra received her PhD from Cardiff University studying the role of the cardiac ryanodine receptor in CPVT and sudden cardiac death. Since completing her PhD in 2009, Debra has worked at various companies including Miltenyi Biotec, GE Healthcare Lifesciences and Cytiva, before moving to MaxCyte, offering dedicated support and advice to their customer base. Please connect with her should a discussion be useful.